ArticleAntimicrobial agents and chemotherapy2010
Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents.
Article in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Eumycetoma causative agents: A systematic review to inform the World Health Organization priority list of fungal pathogens.Medical mycology · 2024Pooled it
- A conserved grain-associated immunosuppressive niche in Sudanese patients with mycetoma.PLoS neglected tropical diseases · 2026Observational
- A drug-repurposing screen of FDA- and EMA-approved drugs identifies two NF-κB inhibitors active against eumycetoma.The Journal of antimicrobial chemotherapy · 2025Article
- An updated list of eumycetoma causative agents and their differences in grain formation and treatment response.Clinical microbiology reviews · 2024Review
- The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo.Medical mycology · 2023Article
- In vitro susceptibility testing for black grain eumycetoma causative agents.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2021Article
- Development and Validation of anAntimicrobial agents and chemotherapy · 2021Article
- Diagnostic implications of mycetoma derived from Madurella pseudomycetomatis isolates from Mexico.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020Article
- Pyomelanin Secretion in Madurella mycetomatis Interferes with Spectrophotometric Endpoint Reading Using the Sensititre YeastOne alamarBlue Assay but Not with Visual Endpoint Reading.Antimicrobial agents and chemotherapy · 2019Article
- Pulmonary Scedosporium apiospermum Infection with Pulmonary Tumorlet in an Immunocompetent Patient.Internal medicine (Tokyo, Japan) · 2018Article
- Addressing the most neglected diseases through an open research model: The discovery of fenarimols as novel drug candidates for eumycetoma.PLoS neglected tropical diseases · 2018Article
- Rapid and Robust Identification of the Agents of Black-Grain Mycetoma by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry.Journal of clinical microbiology · 2017Article
- Novel Taxa Associated with Human Fungal Black-Grain Mycetomas: Emarellia grisea gen. nov., sp. nov., and Emarellia paragrisea sp. nov.Journal of clinical microbiology · 2016Article
- Mycetoma medical therapy.PLoS neglected tropical diseases · 2014Review
- The mycetoma knowledge gap: identification of research priorities.PLoS neglected tropical diseases · 2014Review
- Subcutaneous fungal infections.Current infectious disease reports · 2012Article
- Reshuffling of Aspergillus fumigatus cell wall components chitin and β-glucan under the influence of caspofungin or nikkomycin Z alone or in combination.Antimicrobial agents and chemotherapy · 2012Article
- In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine.Antimicrobial agents and chemotherapy · 2011Article
- Mycetoma: An Update.Indian journal of dermatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eumycetoma caused by Madurella mycetomatis is treated surgically and with high doses of ketoconazole. Therapeutic responses are poor, and recurrent infections are common. In search of therapeutic alternatives in the treatment of mycetoma, we determined the in vitro susceptibilities of M. mycetomatis isolates against caspofungin, anidulafungin, and micafungin. As a comparator fungus, Aspergillus fumigatus was used. Minimal effective concentrations (MECs) and MICs were assessed and compared to those of ketoconazole. M. mycetomatis isolates were not susceptible to the echinocandins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.